Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
出版年份 2020 全文链接
标题
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
作者
关键词
-
出版物
Cancers
Volume 12, Issue 3, Pages 731
出版商
MDPI AG
发表日期
2020-03-20
DOI
10.3390/cancers12030731
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- (2020) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors
- (2019) Zahra Moradpour et al. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System
- (2019) Shweta Joshi et al. Journal of Oncology
- Properties of FDA-approved small molecule protein kinase inhibitors
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) Bernard Escudier et al. ANNALS OF ONCOLOGY
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) D Planchard et al. ANNALS OF ONCOLOGY
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) A Vogel et al. ANNALS OF ONCOLOGY
- Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
- (2019) Collins et al. Cancers
- SO-007Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)
- (2019) H Hara et al. ANNALS OF ONCOLOGY
- Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology
- (2019) Crisci et al. Medicina-Lithuania
- Marrying chemistry with biology by combining on-chip solution-based combinatorial synthesis and cellular screening
- (2019) Maximilian Benz et al. Nature Communications
- Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor‐tyrosine kinase inhibitors in patients with EGFR ‐mutant non‐small cell lung cancer
- (2019) Yoshiya Matsumoto et al. CANCER SCIENCE
- Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study
- (2019) Maximilian J Hochmair et al. Future Oncology
- Deep learning enables rapid identification of potent DDR1 kinase inhibitors
- (2019) Alex Zhavoronkov et al. NATURE BIOTECHNOLOGY
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) O Michielin et al. ANNALS OF ONCOLOGY
- Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) S Filetti et al. ANNALS OF ONCOLOGY
- The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy
- (2019) Fan Liang et al. Oncogenesis
- Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2018) P G Casali et al. ANNALS OF ONCOLOGY
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
- (2018) F Cardoso et al. ANNALS OF ONCOLOGY
- Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
- (2018) Silvia Maifrede et al. BLOOD
- Drug resistance profiles of mutations in the RET kinase domain
- (2018) Xuan Liu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes
- (2018) Zheng Yang et al. International Journal of Biological Sciences
- Opportunities and obstacles for deep learning in biology and medicine
- (2018) Travers Ching et al. Journal of the Royal Society Interface
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
- (2018) Michael B Atkins et al. LANCET ONCOLOGY
- Targeting tumour microenvironment by tyrosine kinase inhibitor
- (2018) Hor-Yue Tan et al. Molecular Cancer
- Kinase-targeted cancer therapies: progress, challenges and future directions
- (2018) Khushwant S. Bhullar et al. Molecular Cancer
- Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
- (2018) Simona Soverini et al. Molecular Cancer
- Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors
- (2018) Anthony W. Tolcher et al. MOLECULAR CANCER THERAPEUTICS
- Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies
- (2018) Peter Makhov et al. MOLECULAR CANCER THERAPEUTICS
- Arsenic trioxide and sorafenib induce synthetic lethality of FLT3-ITD acute myeloid leukemia cells
- (2018) Rui Wang et al. MOLECULAR CANCER THERAPEUTICS
- Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes
- (2018) Spencer S. Watson et al. Cell Systems
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors
- (2018) Pedro Miguel Lacal et al. PHARMACOLOGICAL RESEARCH
- Receptor Tyrosine Kinase-Targeted Cancer Therapy
- (2018) Toshimitsu Yamaoka et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
- (2018) Sunilkumar Kakadia et al. OncoTargets and Therapy
- Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
- (2018) Yi Ding et al. Nature Communications
- Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
- (2018) Holly L Pacenta et al. Drug Design Development and Therapy
- Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
- (2018) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy
- (2017) Yemsratch T. Akalu et al. IMMUNOLOGICAL REVIEWS
- Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
- (2017) Xian Chan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Protein kinase C in cancer: The top five unanswered questions
- (2017) Mariana Cooke et al. MOLECULAR CARCINOGENESIS
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity
- (2017) Akash Patnaik et al. Cancer Discovery
- Implications of KRAS mutations in acquired resistance to treatment in NSCLC
- (2017) Marzia Del Re et al. Oncotarget
- A New Era for Cancer Target Therapies: Applying Systems Biology and Computer-Aided Drug Design to Cancer Therapies
- (2016) Yung-Hao Wong et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination
- (2016) Jason S. L. Yu et al. DEVELOPMENT
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
- (2016) MASARU KATOH INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection
- (2016) Steven Yu et al. OncoTargets and Therapy
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) R. Dummer et al. ANNALS OF ONCOLOGY
- Ten things you should know about protein kinases: IUPHAR Review 14
- (2015) Doriano Fabbro et al. BRITISH JOURNAL OF PHARMACOLOGY
- Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells
- (2015) A. Miyazaki et al. Clinical & Translational Oncology
- The importance of the tumor microenvironment in the therapeutic management of cancer
- (2015) Charles Pottier et al. Expert Review of Anticancer Therapy
- Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors
- (2015) Chun-Han Lin et al. MOLECULAR BIOLOGY OF THE CELL
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
- (2015) Peter B. Alexander et al. Frontiers of Medicine
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Rapid Discovery of a Novel Series of Abl Kinase Inhibitors by Application of an Integrated Microfluidic Synthesis and Screening Platform
- (2013) Bimbisar Desai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance
- (2012) Edita Aksamitiene et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Why imatinib remains an exception of cancer research
- (2012) Steven D. Horne et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors
- (2009) A. W. Gramza et al. CLINICAL CANCER RESEARCH
- Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
- (2009) N. A. Pennell et al. ONCOLOGIST
- G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models
- (2009) F. Shojaei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now